布仑妥昔单抗维多汀
自体干细胞移植
医学
淋巴瘤
肿瘤科
移植
干细胞
内科学
免疫疗法
癌症研究
霍奇金淋巴瘤
癌症
生物
遗传学
作者
Lingyan Ping,Yuqin Song
标识
DOI:10.3760/cma.j.issn.1009-9921.2020.02.002
摘要
In recent years, due to the progress of cell-targeted therapy and the presence of a large number of new drugs, the treatment efficacy and survival of many lymphoma patients have improved. As a traditional treatment method, autologous stem cell transplantation (ASCT) still plays an important role in lymphoma treatment. ASCT can be a curable method in some clinical situations. Many clinical studies in recent years have further confirmed the role of ASCT in high-risk aggressive lymphoma and Hodgkin lymphoma. The efficacy of ASCT can be improved by combining antibodies such as brentuximab vedotin, programmed death 1, programmed death ligand 1 or chimeric antigen receptor T cell therapy, and the recurrence risk of ASCT may be decreased.
Key words:
Lymphoma; Stem cell transplantation; Immunotherapy
科研通智能强力驱动
Strongly Powered by AbleSci AI